- 1 Proteomic associations with forced expiratory volume a Mendelian randomisation study
- 2 Axelsson GT^{1,2}, Jonmundsson T¹, Woo YJ³, Frick EA¹, Aspelund T^{1,5}, Loureiro JJ³, Orth AP⁴, Jennings LL³
- 3 Gudmundsson G^{5,6}, Emilsson V^{1,5}, Gudmundsdottir V^{1,5}, and Gudnason V^{1,5}
- 4 1: Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland.
- 5 2: Landspitali University Hospital, Department of Internal Medicine, 101 Reykjavik, Iceland
- 6 3: Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, MA 02139, USA
- 4: Novartis Institutes for Biomedical Research, 10675 John Jay Hopkins Drive, San Diego, CA 92121,
- 8 USA
- 9 5: Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.
- 10 6: Landspitali University Hospital, Department of Respiratory Medicine and Sleep, 108 Reykjavik,
- 11 Iceland
- 12 Correspondence:
- 13 Keywords: Lung function tests, Forced expiratory volume, Proteomics, Mendelian randomisation
- 14 Word count:
- 15 Main text: 3528
- 16 Abstract: 251
- 17 Author contributions:
- 18 Conceptualization, methodology, and design of the study: GTA, TJ, VaG, GG, VE and ViG.
- 19 Data acquisition: VaG, TA, LLJ, JJL, APO, VE, ViG
- 20 Analysis of the data: GTA, TJ, VaG, EAF, TA, YJW, JJL
- 21 Administration and supervision: VaG, LLJ, GG, VE, ViG
- 22 Drafting of the initial manuscript: GTA, TJ, VaG and ViG.
- 23 All authors revised and/or edited the manuscript for scientific content.
- 24 Funding. The AGES-Reykjavik study was funded by Icelandic Heart Association, National Institute on
- 25 Aging contract N01-AG-12100 and HHSN271201200022C, and Althingi (the Icelandic Parliament).
- 26 GTA was supported by the Eimskip University Fund from the University of Iceland. GG was supported
- 27 by the University of Iceland and by Landspitali University Hospital. TJ and VaG were supported by the
- 28 University of Iceland, VaG by its postdoctoral fund. All protein measurements were funded by
- 29 Novartis.
- 30 Competing interests: The study was supported by the Novartis Institute for Biomedical Research,
- and protein measurements for the AGES-Reykjavik cohort were performed at SomaLogic. JJL, YJW.
- 32 and LLJ are employees and stockholders of Novartis. GTA and GG report travel support from

- 33 Boehringer-Ingelheim for work not related to the study. No other potential conflicts of interest
- relevant to this article were reported.

A decline in forced expiratory volume (FEV1) is a hallmark of obstructive respiratory diseases, an important cause of morbidity among the elderly. While some data exist on biomarkers that are related to FEV1, we sought to do a systematic analysis of causal relations of biomarkers with FEV1.

Data from the general population-based AGES-Reykjavik study were used. Proteomic measurements were done using 4,782 DNA aptamers (SOMAmers). Data from 1,648 participants with spirometric data were used to assess the association of SOMAmer measurements with FEV1 using linear regression. Bi-directional Mendelian randomisation (MR) analyses were done to assess causal relations of observationally associated SOMAmers with FEV1, using genotype and SOMAmer data from 5,368 AGES-Reykjavik participants and genetic associations with FEV1 from a publicly available

46 In observational analyses, 473 SOMAmers were associated with FEV1 after multiple testing

47 adjustment. The most significant were R-Spondin 4, Alkaline Phosphatase, Placental Like 2 and

48 Retinoic Acid Receptor Responder 2. Of the 235 SOMAmers with genetic data, eight were associated

49 with FEV1 in MR analyses. Three were directionally consistent with the observational estimate,

50 Thrombospondin 2 (THBS2), Endoplasmic Reticulum Oxidoreductase 1 Beta and Apolipoprotein M.

51 THBS2 was further supported by a colocalization analysis. Analyses in the reverse direction, testing

whether changes in SOMAmer levels were caused by changes in FEV1, were performed but no

53 significant associations were found after multiple testing adjustments.

In summary, this large scale proteogenomic analyses of FEV1 reveals protein markers of FEV1, as

well as several proteins with potential causality to lung function.

55

52

35

36

37

38

39

40

41 42

43

44

45

GWAS (n = 400,102).

Introduction

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) are a leading global cause of mortality and morbidity, with their relative importance increasing in the last decades (1). Diagnosis of COPD is based on obstruction on pulmonary function testing, by a low forced expiratory volume in one second (FEV₁) relative to the forced vital capacity (FVC), and a progressive decline in pulmonary function is a hallmark of the disease (2). While it is undisputed that exposure to external harmful stimuli such as cigarette smoke and biomass fumes are substantial risk factors for pulmonary function decline, intrinsic factors such as genetics and gene-environment interactions play a significant part as well (2-4). Genome wide association studies (GWAS) have found several genetic polymorphisms that are associated with COPD and lung function decline, including polymorphisms in or near genes encoding matrix metalloproteinase 12, nicotinic acetylcholine receptor, hedgehog interacting protein, glutathione S-transferase, C-terminal domain-containing protein (5-9) and the antiprotease alpha-1-antitrypsin (10). In addition to genetic polymorphisms, biomarkers that predict COPD or lung function have been discovered. Among them are inflammatory markers, soluble receptor for advanced glycoprotein end products (AGER), club cell secretory protein 16 (SCGB1A1) and surfactant protein D (SFTPD) (11-14). For several of these biomarkers, estimations of potential causality have been made. AGER, SCGB1A1 and SFTPD have been suggested to be causally associated with COPD or with lung function, while analyses have pointed against such an association for the inflammatory markers CRP and IL-6 (15-19). Still, while substantial epidemiologic data exist regarding single genetic markers and biomarkers that predict COPD or lung function, a systematic large-scale analysis of observational and causal associations of protein markers with lung function has not been undertaken to our knowledge. Proteomics have emerged as a way of exploring biologic predictors of disease, especially with the advent of methods that allow for measurement and evaluation of thousands of proteins in biological samples from participants of large cohort studies (20). In addition to predicting disease and diseaserelated outcomes, integration of genetic data allows one to make assumptions regarding causality with proteomic markers. Mendelian randomization (MR) is such a method and utilizes genetic polymorphisms as instrumental variables to assess the relationship of an exposure with an outcome. As chromosomal alleles are randomly allocated during gamete formation, this methodology allows one to avoid the effect of confounders and to infer causality from epidemiologic data (21). The aim of the study was to systematically explore the associations of a multitude of protein markers with lung function and then to assess the potential causal relationships of these protein markers

with lung function by use of bi-directional Mendelian randomization.

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

Methods Study phenotyping The Age/Gene Environment Susceptibility (AGES)-Reykjavik study is a population-based cohort study of 5,764 elderly Icelanders that was carried out between 2002 and 2006. The participants, aged from 66 to 96 years (mean 76 years), were all prior participants of the Reykjavik Study done decades earlier. As part of AGES-Reykjavik, the participants underwent extensive phenotyping by questionnaires, physiological measurements, imaging studies and laboratory measurements, during a single clinic visit. The study was approved by the Icelandic National Bioethics Committee (VSN-00-063) and the Institutional Review Board of the Intramural Program of the National Institute for Aging, with informed consent obtained from all participants. Further details of the study design are previously published (22). A subset of the study participants underwent lung function testing in a standardised manner. The device used was a Vitalograph Gold Standard Plus (Vitalograph Ltd., UK). Each participant completed three attempts. Participants with spirometry of acceptable quality were included (n = 1,660). Spirometry measures from participants that completed at least two attempts with a no more than 300 ml difference between the attempts and exhalation for at least 6 seconds were deemed acceptable (23). Smoking history was ascertained from questionnaires while anthropometric measurements were done during the clinic visit. Protein measurements were done in serum samples from participants using a high throughput proteomics technology, the SOMAscan (SomaLogic, Boulder, CO) in which DNA aptamers (Slow-Off Rate Modified Aptamers (SOMAmers)) bind to target protein epitopes and are then quantified with the help of fluorescence after wash-out of unbound aptamers and proteins. Measurements in AGES-Reykjavik were done with a 5,034 SOMAmer platform in serum from 5,457 AGES-Reykjavik participants, targeting 4,135 individual human proteins. For the analyses, 4,782 SOMAmers targeting human proteins were used. Measurement data were transformed using Box-Cox transformation and extreme outliers were excluded, as previously described (24). Statistical analyses A flow chart of study design is shown in Figure 1. Descriptive statistics were compiled for participants with acceptable pulmonary function tests, demographic covariate data and protein measurements available (n = 1,648). Using data from these participants, the association of all

participants with acceptable pulmonary function tests, demographic covariate data and protein measurements available (n = 1,648). Using data from these participants, the association of all measured human SOMAmers (n = 4,782) with FEV_1 was assessed using linear regression modelling. These analyses were adjusted for variables that are commonly used to predict FEV_1 in clinical practice, age, sex, height, age squared, and height squared (25). Adjustment for multiple testing was

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140141

142

143

144

145

146

147148

149

150

151

152

153

154

155

156

done using the Benjamini-Hochberg False Discovery Rate (FDR). To understand how tobacco smoking affected these associations, the analyses were repeated with participants stratified by smoking history (ever-smokers versus never-smokers). Genes encoding proteins significantly associated with the outcome after adjustment for multiple testing were subjected to over-representation analysis of Gene Ontology terms (26). In secondary analyses we explored the protein associations with additional outcomes, including FVC, FEV₁/FVC ratio and COPD. Additional covariates included smoking status, pack years of smoking, weight and eGFR.

For SOMAmers that were associated with FEV₁ after adjustment for multiple testing, a bidirectional two-sample MR analysis was performed for the association of SOMA mers with FEV_1 . MR analyses were done for SOMAmers that were observationally associated with FEV1 and had genetic instruments available. Genetic instruments for SOMAmers were defined as follows. The associations of single-nucleotide polymorphisms (SNPs) with SOMAmers were calculated using data from 5,368 participants of AGES-Reykjavik, as previously published and described in detail (24). The possible instrumental variables for each SOMAmer were defined as SNPs located within a cis-window near the gene coding for the protein measured by the SOMAmer, defined as within 500 kb up- and downstream of the gene. SNPs with a window-wide significant association (p < 0.05/number of SNPs in cis-window) with a given SOMAmer were considered as potential instruments. For each gene, SNPs were filtered based on linkage disequilibrium (LD; $r^2 < 0.2$) or distance (>1 mb) using Plink v1.9. Instruments were considered valid if F > 10 for the association of instruments with SOMAmers. The associations of the instrumental variables with FEV1 were obtained from a GWAS of lung function in which data from two cohorts, UKBiobank and SpiroMeta Consortium, were meta-analysed. The total number of participants in that analysis was 400,102 (27). A MR analysis in the reverse direction was performed using all observationally associated SOMAmers as outcomes. Genetic instruments for FEV1 were defined based on the same GWAS on lung function as described above (27). For these analyses, SNPs associated with FEV₁ (p < 5×10^{-8}) were used as instruments after clumping within a cis-window 5 mb up- and downstream of the gene, by an LD threshold of 0.01. The associations of the instrumental variables with SOMAmer levels were obtained from AGES-Reykjavik data (24).

For the MR analyses, SNPs were harmonised using the TwoSampleMR R package. The MR estimates for FEV₁ were obtained using the generalized weighted least squares (GWLS) method, accounting for correlation between instruments (28), except for instances where only one instrument was available, in which Wald ratios were calculated. For each MR analysis with more than two instruments, sensitivity analyses using the weighted median and Egger estimators were done to assess the validity of instruments and limit the effect of pleiotropic associations, respectively. Results were considered to pass these sensitivity analyses when the following

respectively. Results were considered to pass these sensitivity analyses when the following

conditions were met. For the weighted median estimator, the weighted median estimate had to be significant and directionally consistent with the GWLS estimate and for Egger, the Egger estimate had to be directionally consistent with the GWLS estimate and the intercept not significant. In analyses in the reverse direction, estimates were obtained using the inverse variance weighted method. Adjustment for multiple testing was done using the Benjamini-Hochberg False Discovery Rate (FDR).

A colocalization analysis was performed to provide additional causal support for analytes associated with FEV1 in MR analyses. In that aim, AGES-Reykjavik serum pQTLs (24), summary statistics for FEV1 (29) and plasma pQTLs from deCODE (30) were harmonized to account for strand orientation and differences in genome builds. All studies were lifted over to build GRCh38 for colocalization when needed. For the QTLs, only putative cis-regulatory variants were examined defined by 500kb away from the gene body. All regions with variants that had associations of P < 1x10⁻⁵ were fine-mapped using Sum of Single Effects (SuSiE) (31) based on 1000 genome population reference (32). 95% credible-sets were filtered and colocalization between GWAS and QTLs was performed using fastENLOC using the posterior inclusion probabilities estimated in SuSiE (31, 33). Regional colocalization probability (RCP) was calculated by summing the colocalization probability within each 95% credible-set and filtered colocalization results at RCP > 80% for further examination. RCP represents the probability that a given genomic region contains a single colocalized variant (34). Visualization was done using Julia 1.7 and libraries within (35).

Visualization was done using Julia 1.7 and libraries within (35).

Results

177

178 The protein profile of pulmonary function 179 Descriptive statistics for participants that had pulmonary function testing data are shown in Table 1. 180 A majority of participants were female (56%) and participants were on average 76 years old. Most 181 participants had a history of smoking (59%). 182 Of the 4,782 SOMAmers tested, 473 were observationally associated with FEV₁ after adjustment for 183 multiple testing (Table 2, Table S1, Figure 2). The most significantly associated SOMAmers measured were R-Spondin 4 (RSPO4, β = -0.099, p = 1.13×10⁻¹³), Alkaline Phosphatase, Placental Like 2 (ALPPL2, 184 185 $\beta = -0.084$, p = 4.76×10⁻¹¹), Retinoic Acid Receptor Responder 2 (RARRES2, $\beta = -0.093$, p = 7.03×10⁻¹¹), Sushi, Von Willebrand Factor Type A, EGF And Pentraxin Domain Containing 1 (SVEP1, $\beta = -0.085$, p =186 1.67×10^{-10}) and Polymeric Immunoglobulin Receptor (PIGR, $\beta = -0.080, 1.80 \times 10^{-10}$). Results for 187 188 proteins that have been previously suggested as biomarkers of FEV₁ (11) are shown in Table S2. Prior 189 associations of SFTPD (beta = -0.05, p = 0.0002), CRP (beta = -0.06, p = 1.2×10^{-7}), fibringen (beta = -0.04, p = 0.0008 for the stronger associated SOMAmer), IL6 (beta = -0.05, p = 9.6×10^{-5} for the 190 191 stronger associated SOMAmer) and eotaxin (beta = -0.05, p = 0.0002) were reproduced in the AGES-192 Reykjavik data while associations for other suggested biomarkers of FEV₁ were not. 193 The proteins most significantly associated with FEV1 overall also had strong associations with FEV1 among ever-smokers, such as RSPO4 ($\beta = -0.106$, p = 4.83×10^{-9}), RARRES2 ($\beta = -0.11$, p = 1.19×10^{-8}) 194 and ALPPL2 ($\beta = -0.092$, p = 5.73×10⁻⁸). Trefoil Factor 2 (TFF2, $\beta = -0.095$, p = 3.84×10⁻⁸), Complement 195 9 (C9, β = -0.095, p = 5.65×10⁻⁸) and TIMP Metallopeptidase Inhibitor 1 (TIMP1, β = -0.122, p = 196 197 1.18×10⁻⁷) also had notably strong associations with the outcome. However, associations of these 198 proteins were much weaker among never-smokers, with the strongest associations observed for two 199 SOMAmers measuring SVEP1 (β = -0.081, p = 4.52×10⁻⁶ for the stronger associated SOMAmer) (Table 200 S3) in this subgroup. The proteins associated with FEV1 were most strongly enriched for Gene 201 Ontology (GO) terms related to humoral immune response, regulation of neurogenesis, compliment 202 activation and extracellular matrix organization (Figure S1, Table S4). 203 Secondary analyses showed a large overlap between the protein profile of FEV₁ compared to that of 204 FVC, FEV₁/FVC ratio and COPD, with some additional proteins detected (204 significant SOMAmers in 205 primary analysis were among 497 significant SOMAmers in secondary analyses; Tables S8-S15). 206 Mendelian randomization analysis 207 Of 473 SOMAmers associated with FEV₁, 235 (50%) had genetic instruments available and were 208 included in MR analyses of the association of SOMAmers with FEV₁. The instruments are shown in

Table S5 for significant SOMAmers. Of the 235 SOMAmers tested, eight were significantly associated with FEV $_1$ in MR analyses (Table 3), suggesting they may have a causal effect on lung function. Of those, three, Thrombospondin 2 (THBS2, β = -0.037, p = 9.53×10 $^{-5}$), Endoplasmic Reticulum Oxidoreductase 1 Beta (ERO1B, β = -0.025, p = 8.05×10 $^{-4}$) and Apolipoprotein M (APOM, β = 0.053, p = 9.72×10 $^{-4}$) were directionally consistent with the observational analyses. The other five SOMAmers with significant causal estimates, R-Spondin-2 (RSPO2), TIMP Metallopeptidase Inhibitor 4 (TIMP4), CD14, Heparin Binding Growth Factor (HDGF) and Parkinsonism Associated Deglycase (PARK7) were directionally inconsistent. Table 3 and Figure 4 show the 29 SOMAmers that were nominally associated with FEV $_1$ (unadjusted p < 0.05) using MR and passed weighted median sensitivity testing. Among nominally associated SOMAmers, the directional consistency between causal and observational estimates was low, or 38%, suggesting that the potentially causal effects of the protein are generally not reflected in the observational estimates. Of the five previously suggested biomarkers of FEV $_1$ listed in Table S2 that were observationally associated with FEV $_1$, only three proteins had genetic instruments available, the acute phase reactants CRP and fibrinogen as well as eotaxin. None of these proteins were significantly associated with FEV $_1$ in MR analyses (Table S6).

The 29 proteins identified from the MR analysis (Table 3) were further examined for colocalization evidence. Among the 8 proteins with significant MR association, a 3' UTR variant (rs3253) from the FEV1 GWAS colocalized with THBS2 protein expression in AGES-Reykjavik (P = 1.4×10^{-19} , β = -0.18, RCP=0.9976). The same variant was associated with THBS2 protein expression in the deCODE cohort (P = 2.1×10^{-186} , β =-0.26) (Table 4, Figure 4). Among 22 proteins with nominal association with MR analysis, an upstream variant (rs4968200) from the FEV1 GWAS colocalized with TNFSF12 protein levels in AGES-Reykjavik (P = 5.6×10^{-133} , β = 0.63, RCP = 0.9995).

Finally, all 473 SOMAmers observationally associated with FEV₁ were included in a MR analysis in the reverse direction, i.e., to evaluate if the changes in SOMAmer levels are downstream of changes in lung function. FEV₁ was not causally associated with levels of any SOMAmers after adjustment for multiple testing. Data for the 18 SOMAmers that FEV₁ was nominally associated with (p < 0.05) in the reverse-MR analysis are shown in Table S7.

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257258

259

260

261

262

263

264

265

266

267

268

269

270

Discussion We present findings from a proteomic analysis of pulmonary function with more candidate protein analytes than previously published to our knowledge (11), highlighting several proteins as strong markers of FEV₁. Stratification by smoking shows that most associations are driven by ever-smokers. Mendelian randomisation was systematically applied to the candidate markers, revealing proteins whose levels may have a causal effect on lung function. Reverse causation analyses failed to demonstrate that protein level changes associated with lung function occur downstream of the phenotype change, although this could partly be due to insufficient power in the FEV1 GWAS. Among the proteins identified through MR analysis, probabilistic colocalization pointed towards THBS2 and TNFSF12 as putative upstream targets for COPD. Eight proteins were suggested to be causally implicated in lung function based on the MR analysis. However, only three (THBS2, ERO1B and APOM) had consistent direction of effect for the observational and causal estimates. Such discrepancy has been observed when comparing causal and observational estimates (36, 37) for serum proteins. Based on probabilistic quantification, a 3' UTR variant within THBS2 was identified as a putative causal variant for FEV1 changes and this lead variant colocalized with THBS2 protein expression in AGES-Reykjavik (Table 4, Figure 4). The effect of this variant was replicated in an independent cohort for THBS2 protein levels (Table 4, Figure 4). Because directions of effects were consistent across the datasets and THBS2 had non-revertible causal association to FEV1, supported by colocalization, THBS2 may be a candidate target for COPD. THBS2 is an extracellular matrix protein that has been implicated in various cardiovascular disorders and is also a candidate biomarker for non-small cell lung cancer (38, 39). THBS2 is involved in tissue repair and interacts with many different ligands in the extracellular matrix, among them matrix metalloproteases and elastase (40). Although mechanism of THBS2 needs further experimental validation, our work suggests that protein levels of THBS2 may be a target for extracellular matrix and regenerative properties associated with COPD. Meanwhile, ERO1B is a disulfide oxidase in the endoplasmic reticulum that is shown to predict survival in pancreatic and pulmonary cancers (41-43) and APOM, an apolipoprotein that is mainly a component of high density lipoproteins and has been associated with COPD severity (44). Genetic variants flanking this gene have been associated with obstructive spirometry measurements (45). However, it must be kept in mind that the association of APOM is based on a single SNP, rs2736163, which is intronic to PRRC2A. Despite not reaching the study threshold for statistical significance, some proteins that were nominally associated in MR analyses are of interest. First, alpha-1-antitrypsin (SERPINA1) is the best-

known protein known to cause COPD as severe deficiency of alpha-1-antitrypsin results in

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

obstructive lung disease (46). However, in our data, serum levels of alpha-1-antitrypsin are inversely associated with FEV1 in both observational and MR analyses, contrary to what would possibly be expected, although this directionality is known from previous observational analyses of FEV1 and explained by alpha-1-antitrypsin's role as an acute phase reactant (47). Also, polymorphisms that cause mild or intermediate alpha-1-antitrypsin deficiency are not consistently associated with decreased lung function, suggesting that levels of the protein may only affect lung function below a threshold level (48). Second, TNFSF12 was a protein with a colocalizing pQTL variant with the FEV1 GWAS (Table 4, Figure 4). TNFSF12 is a member of the Tumor Necrosis Factor (TNF) superfamily, of which one key cytokine, TNF-alpha, is a well-known protein target disrupted in COPD patients (49). Despite a concrete association between TNF-alpha levels and COPD in both human and murine models (49-51), TNF-alpha monoclonal antibody was a failure as a COPD therapy (52). This is likely due to COPD being a highly complex inflammatory disease in which single cytokine blockage may not be sufficient for treating the disease. These additional TNF family proteins with MR based causal evidence and probabilistic colocalization may be novel targets for COPD patients impacted by TNFalpha associated pathobiology. Notable other nominally significant or directionally inconsistent proteins in the findings are matrix metalloproteinase 8 (MMP-8), one of the proteases observationally associated with lung function and implicated in the pathogenesis of COPD (53, 54), TIMP4, an inhibitor of matrix metalloproteinases that has been shown to be upregulated in COPD patients (55) and CD14, levels of which have been shown to be elevated in lungs of smokers (56). While only 8 proteins were significantly associated with FEV₁ in MR analyses, FEV₁ was not associated with any proteins in analyses in the reverse direction. The data were therefore unable to support prior causal analyses involving inflammatory markers that have suggested reverse causality of FEV1 with inflammatory markers (18) (Table S6). The study reveals novel markers with strong observational relations to lung function such as RSPO4, a signalling molecule that is part of the Wnt signalling pathway (57), the tumor marker ALPPL2 (58), the adipokine chemerin (RARRES2), and SVEP1, a protein that is thought to play a role in inflammation in atherosclerosis (59). In addition, the findings validate the observational associations of some of the previously suggested protein markers of FEV₁, such as SFTPD, fibrinogen, eotaxin and CRP (Table S2) (13), while the associations of other previously suggested biomarkers of FEV₁ such as AGER were not corroborated in this study (13, 60). Finally, the findings show that proteins that take part in immune responses and extracellular matrix modulation are over-represented among the proteins related to FEV₁. This work is subject to a number of limitations. First, the study is based on SOMAmer technology, a relatively novel aptamer-based technology for protein measurements. While many of these

elatively novel aptamer-based technology for protein measurements. While many of these

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

SOMAmers have been validated with encouraging results, it has been pointed out that a minority of SOMAmers could be subject to cross-reactivity with related or homologous proteins (20). Second, both the AGES-Reykjavik cohort and the UKBiobank and SpiroMeta Consortium are of European ancestry (27). Therefore, the observed associations could not be generalizable to other populations. Additionally, the AGES-Reykjavik cohort is older than the UKBiobank and SpiroMeta Consortium which could distort comparisons between observational and genetic findings. Third, the measure of lung function used in this paper, FEV₁, is disproportionally impaired in obstructive lung disease and is a key diagnostic parameter for such diseases. While COPD is the archetypal obstructive lung disease, especially among the elderly, the presence of other respiratory diseases such as asthma could influence the findings, especially in younger cohorts. Fourth, subtle differences in genetic structure between AGES, UKBiobank, and SpiroMeta cohorts is present and may be contributing to the lack of colocalization for the other 6 MR identified proteins. For instance, very few MR instruments used overlapped with 95% credible-sets identified (Supplementary Table 16). In comparisons to UKBioBank, missing variants in AGES-Reykjavik cohort may contribute to colocalization false negatives. Lastly, many causal estimates are directionally inconsistent with observational estimates. While this phenomenon is known from previous proteogenomic studies, its reasons are unclear. In conclusion, this proteogenomic analysis reveals several proteins that are potentially causally related to lung function, most notably THBS2, ERO1B and APOB.

Figure 1 – A flow chart of the study design

Figure 2 – A volcano plot showing the observational associations of all 4782 SOMAmers with FEV1

Figure 3 – A forest plot showing the observational and mendelian randomisation estimates for FEV1 for causally associated SOMAmers

Figure 4. Colocalization plot for *THBS2*. FEV1 GWAS (29), AGES pQTL (24), and DECODE pQTL (30) data are shown from top to bottom. Grey circles are individual SNPs from each study. Both purple diamond and red vertical line represent the lead variant (rs3253, 3' UTR variant). X-axis is genomic position within chromosome 6 and y-axis is -log10 transformed P-values. Purple horizontal lie delineates GWAS threshold at 5x10⁻⁸ and yellow vertical lines represent gene boundary for *THBS2*. Visualization is restricted to 150,000 bp upstream and downstream of THBS2. Linkage disequilibrium (r²) within the region is plotted at the bottom in green.

Tables

337

338

Table 1 – Overview of study participants

n	1648
Sex = Female (%)	917 (55.6)
Age (mean (SD))	76.28 (5.70)
Height (mean (SD))	167.22 (9.48)
Weight (mean (SD))	75.61 (14.67)
BMI (mean (SD))	26.97 (4.38)
Eversmoker (%) [†]	969 (59.4)
FEV ₁ (mean (SD))	2.12 (0.69)
$FEV_1\%$ of predicted (mean (SD))*	0.89 (0.21)
FVC (mean (SD))	2.97 (0.83)
FVC % of predicted (mean (SD))*	0.92 (0.17)
FEV₁/FVC < 70% (%)	578 (35.1)

^{† 17} participants had missing smoking data.

^{*} Predicted values based on Hankinson et al. (25)

Table 2 – Observational associations of highly-associated proteins with FEV₁

SOMA	EGS	β	95% CI	P	FDR P
8464_31_3	RSPO4	-0.099	-0.1250.073	1.13×10 ⁻¹³	5.39×10 ⁻¹⁰
7813_6_3	ALPPL2	-0.084	-0.1090.059	4.76×10 ⁻¹¹	1.12×10 ⁻⁷
3079_62_2	RARRES2	-0.093	-0.1210.065	7.03×10 ⁻¹¹	1.12×10 ⁻⁷
11178_21_3	SVEP1	-0.085	-0.1110.059	1.67×10 ⁻¹⁰	1.72×10 ⁻⁷
3216_2_2	PIGR	-0.08	-0.1040.056	1.80×10 ⁻¹⁰	1.72×10 ⁻⁷
11109_56_3	SVEP1	-0.084	-0.110.058	3.39×10 ⁻¹⁰	2.70×10 ⁻⁷
2292_17_4	C9	-0.079	-0.1030.054	4.55×10 ⁻¹⁰	3.11×10 ⁻⁷
12549_33_3	HPGDS	0.079	0.054 - 0.103	6.02×10 ⁻¹⁰	3.60×10 ⁻⁷
6379_62_3	ADAMTSL2	-0.082	-0.1090.055	2.40×10 ⁻⁹	1.27×10 ⁻⁶
9191_8_3	TFF2	-0.076	-0.1010.051	3.47×10 ⁻⁹	1.66×10 ⁻⁶
8841_65_3	CILP2	0.074	0.049 - 0.099	4.47×10 ⁻⁹	1.95×10 ⁻⁶
8323_163_3	TFF3	-0.079	-0.1060.053	4.98×10 ⁻⁹	1.99×10 ⁻⁶
6390_18_3	NPS	0.077	0.051 - 0.103	8.04×10 ⁻⁹	2.96×10 ⁻⁶
2211_9_6	TIMP1	-0.096	-0.1290.062	2.00×10 ⁻⁸	6.50×10 ⁻⁶
13722_105_3	C9	-0.07	-0.0940.046	2.06×10 ⁻⁸	6.50×10 ⁻⁶
6605_17_3	IGFALS	0.07	0.046 - 0.095	2.18×10 ⁻⁸	6.50×10 ⁻⁶
12707_26_3	DPYSL3	0.07	0.046 - 0.095	2.75×10 ⁻⁸	7.72×10 ⁻⁶
5728_60_3	FCRL1	0.069	0.044 - 0.093	5.29×10 ⁻⁸	1.40×10 ⁻⁵
6075_61_3	HEXB	0.071	0.045 - 0.097	9.08×10 ⁻⁸	2.22×10 ⁻⁵
4496_60_2	MMP12	-0.069	-0.0940.044	9.28×10 ⁻⁸	2.22×10 ⁻⁵
6225_3_3	PRSS8	0.072	0.046 - 0.099	1.07×10 ⁻⁷	2.43×10 ⁻⁵
4337_49_2	CRP	-0.063	-0.0870.04	1.18×10 ⁻⁷	2.57×10 ⁻⁵
10620_21_3	MSMB	-0.07	-0.0960.044	1.28×10 ⁻⁷	2.67×10 ⁻⁵
2609_59_2	CST3	-0.075	-0.1030.047	2.09×10 ⁻⁷	4.05×10 ⁻⁵
8885_6_3	CACNA2D3	0.067	0.042 - 0.092	2.11×10 ⁻⁷	4.05×10 ⁻⁵

Results of linear regression analyses adjusted for sex, age, age squared, height and height squared.

³⁴³ Results are shown for the proteins with the most significant associations.

Table 3 – Results of Mendelian randomisation analysis of the association of proteins with FEV₁

SOMA	Protein	nSNP	B - MR	SE	P - MR	FDR P - MR	Egger	B - Obs	P - Obs	FDR P - Obs
8409_3_3	RSPO2	3	0.109	0.023	2.44×10 ⁻⁶	5.73×10 ⁻⁴	Yes	-0.064	1.52×10 ⁻⁶	1.75×10 ⁻⁴
3339_33_1	THBS2	24	-0.037	0.009	9.53×10 ⁻⁵	7.85×10 ⁻³	Yes	-0.062	1.96×10 ⁻⁶	2.09×10 ⁻⁴
6462_12_3	TIMP4	17	0.028	0.007	1.00×10 ⁻⁴	7.85×10 ⁻³	Yes	-0.05	1.70×10 ⁻⁴	5.29×10 ⁻³
8969_49_3	CD14	6	0.084	0.024	5.85×10 ⁻⁴	0.034	Yes	-0.045	2.21×10 ⁻³	0.029
7994_41_3	ERO1B	12	-0.025	0.007	8.05×10 ⁻⁴	0.038	Yes	-0.036	3.78×10 ⁻³	0.042
14125_5_3	APOM	1	0.053	0.016	9.72×10 ⁻⁴	0.038	-	0.041	1.12×10 ⁻³	0.018
8953_47_3	HDGF	7	0.028	0.009	1.26×10 ⁻³	0.041	Yes	-0.054	5.10×10 ⁻⁵	2.26×10 ⁻³
9845_33_3	PARK7	2	-0.056	0.017	1.40×10 ⁻³	0.041	•	0.036	4.63×10 ⁻³	0.048
2668_70_2	CAPN1	3	-0.051	0.016	1.94×10 ⁻³	0.051	Yes	0.04	2.93×10 ⁻³	0.035
3290_50_2	CD109	49	-0.013	0.005	4.91×10 ⁻³	0.111	Yes	0.044	4.23×10 ⁻⁴	0.01
2797_56_2	APOB	9	-0.029	0.011	5.18×10 ⁻³	0.111	Yes	0.054	2.39×10 ⁻⁵	1.28×10 ⁻³
3580_25_8	SERPINA1	9	-0.027	0.01	6.03×10 ⁻³	0.118	Yes	-0.055	3.11×10 ⁻⁵	1.61×10 ⁻³
12395_86_3	DARS2	2	-0.058	0.022	9.64×10 ⁻³	0.164	-	-0.037	3.09×10 ⁻³	0.036
5939_42_3	TNFSF12	77	0.011	0.004	0.01	0.164	Yes	0.037	3.33×10 ⁻³	0.038
8427_118_3	RSPO3	17	0.033	0.013	0.01	0.164	Yes	-0.06	1.68×10 ⁻⁵	9.92×10 ⁻⁴
2630_12_2	IL1RAP	58	0.006	0.002	0.018	0.259	No	0.037	3.38×10 ⁻³	0.038
5070_76_3	TNFRSF6B	3	0.174	0.075	0.02	0.283	Yes	-0.044	3.14×10 ⁻⁴	8.25×10 ⁻³
8992_1_3	TMEM2	1	-0.052	0.023	0.025	0.312	=	0.043	5.41×10 ⁻⁴	0.012
8288_27_3	APOH	5	-0.032	0.014	0.025	0.312	Yes	0.044	7.37×10 ⁻⁴	0.014
13130_150_3	HK2	2	-0.04	0.019	0.032	0.338	=	-0.042	8.84×10 ⁻⁴	0.015
9870_17_3	WARS	5	-0.021	0.01	0.032	0.338	Yes	0.041	1.31×10 ⁻³	0.02
4297 <u>62</u> 3	SPON1	8	-0.026	0.012	0.032	0.338	Yes	-0.052	1.17×10 ⁻⁴	3.93×10 ⁻³
2789_26_2	MMP7	8	0.02	0.009	0.033	0.338	Yes	-0.054	2.53×10 ⁻⁵	1.34×10 ⁻³
9172_69_3	MMP8	13	-0.014	0.007	0.036	0.343	Yes	-0.041	1.03×10 ⁻³	0.017
5646_20_3	RNASE6	33	0.008	0.004	0.037	0.343	Yes	-0.048	1.95×10 ⁻⁴	5.80×10 ⁻³
4546_27_3	ADGRE2	29	0.012	0.006	0.039	0.343	Yes	0.057	7.36×10 ⁻⁶	5.41×10 ⁻⁴
3449_58_2	SERPINA4	56	-0.007	0.004	0.039	0.343	Yes	0.04	1.42×10 ⁻³	0.021
10746_24_3	DKK3	6	-0.031	0.015	0.044	0.356	Yes	0.049	2.10×10 ⁻⁴	6.09×10 ⁻³
12387_7_3	PDLIM4	11	-0.025	0.012	0.044	0.356	Yes	0.046	5.08×10 ⁻⁴	0.011

Shown are data for SOMAmers that had nominally significant associations using Mendelian randomisation and passed weighted median sensitivity analyses. In the column with results from Egger analyses, "Yes" denotes passing the sensitivity test, "No" denotes failing and "-" denotes insufficient number of SNPs to perform the test. Observational data are adjusted for sex, age, age squared, height and height squared.

Bold = Significantly associated with FEV_1 in MR analyses after multiple testing correction.

Italic = Consistent in direction between MR analyses and observational analyses

Table 4. Statistics for the variants with strong colocalization (RCP > 0.9)

gene	SNP	RCP	GWAS	AGES	deCODE
		(FEV1 x AGES)	P-value [beta]	P-value [beta]	P-value [beta]
THBS2	rs3253 ¹	0.9976	1.3x10 ⁻¹⁰ [0.02]	1.4x10 ⁻¹⁹ [-0.18]	2.1x10 ⁻¹⁸⁶ [-0.26]
THBS2	rs7756742 ¹	0.9775	6.3x10 ⁻¹⁰ [0.02]	2.8x10 ⁻¹⁹ [-0.19]	3
THBS2	rs7771838 ¹	0.971	7.0x10 ⁻¹⁰ [0.02]	1.8x10 ⁻¹⁹ [-0.19]	³
TNFSF12	rs4968200 ²	0.9995	4.5x10 ⁻¹¹ [0.02]	5.6x10 ⁻¹¹³ [0.63]	³

RCP: Regional Colocalization Probability

354

355

356

357

358

359

360

¹ Lead variant in FEV1 GWAS is rs3253

² Lead variant in FEV1 GWAS is rs4968200

³ Variant data was not available in DECODE

References

361

- 363 1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369
- diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for
- the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204-22.
- 366 2. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global Strategy for
- the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Am J Respir
- 368 Crit Care Med. 2013;187(4):347-65.
- 369 3. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. The Lancet.
- 370 2006;367(9518):1216-9.
- 371 4. Gordon SB, Bruce NG, Grigg J, Hibberd PL, Kurmi OP, Lam KB, et al. Respiratory risks from
- 372 household air pollution in low and middle income countries. The Lancet Respiratory medicine.
- 373 2014;2(10):823-60.
- 5. Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, et al. MMP12,
- Lung Function, and COPD in High-Risk Populations. N Engl J Med. 2009;361(27):2599-608.
- 376 6. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, et al. Variants in FAM13A
- are associated with chronic obstructive pulmonary disease. Nat Genet. 2010;42(3):200-2.
- 378 7. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, et al. A Genome-Wide Association Study
- in Chronic Obstructive Pulmonary Disease (COPD): Identification of Two Major Susceptibility Loci.
- 380 PLOS Genetics. 2009;5(3):e1000421.
- 381 8. Soler Artigas M, Wain LV, Repapi E, Obeidat M, Sayers I, Burton PR, et al. Effect of five
- 382 genetic variants associated with lung function on the risk of chronic obstructive lung disease, and
- their joint effects on lung function. Am J Respir Crit Care Med. 2011;184(7):786-95.
- 384 9. Cho MH, McDonald M-LN, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, et al. Risk loci for
- chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. The Lancet Respiratory Medicine. 2014;2(3):214-25.
- 387 10. Wood AM, Stockley RA. Alpha One Antitrypsin Deficiency: From Gene to Treatment.
- 388 Respiration. 2007;74(5):481-92.
- 389 11. Serban KA, Pratte KA, Bowler RP. Protein Biomarkers for COPD Outcomes. Chest.
- 390 2021;159(6):2244-53.
- 391 12. Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, et al. Lessons from ECLIPSE: a
- review of COPD biomarkers. Thorax. 2014;69(7):666.
- 393 13. Zemans RL, Jacobson S, Keene J, Kechris K, Miller BE, Tal-Singer R, et al. Multiple biomarkers
- predict disease severity, progression and mortality in COPD. Respir Res. 2017;18(1):117.
- 395 14. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive
- 396 pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax.
- 397 2004;59(7):574.
- 398 15. Keefe J, Yao C, Hwang S-J, Courchesne P, Lee GY, Dupuis J, et al. An Integrative Genomic
- 399 Strategy Identifies sRAGE as a Causal and Protective Biomarker of Lung Function. Chest.
- 400 2022;161(1):76-84.
- 401 16. Milne S, Li X, Hernandez Cordero AI, Yang CX, Cho MH, Beaty TH, et al. Protective effect of
- 402 club cell secretory protein (CC-16) on COPD risk and progression: a Mendelian randomisation study.
- 403 Thorax. 2020;75(11):934.
- 404 17. Obeidat M, en, Li X, Burgess S, Zhou G, Fishbane N, et al. Surfactant protein D is a causal risk
- 405 factor for COPD: results of Mendelian randomisation. Eur Respir J. 2017;50(5):1700657.
- 406 18. Dahl M, Vestbo J, Zacho J, Lange P, Tybjærg-Hansen A, Nordestgaard BG. C reactive protein
- 407 and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax.
- 408 2011;66(3):197.

- 409 19. van Durme YMTA, Lahousse L, Verhamme KMC, Stolk L, Eijgelsheim M, Loth DW, et al.
- 410 Mendelian Randomization Study of Interleukin-6 in Chronic Obstructive Pulmonary Disease.
- 411 Respiration. 2011;82(6):530-8.
- 412 20. Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, et al. Co-regulatory
- 413 networks of human serum proteins link genetics to disease. Science. 2018;361(6404):769-73.
- 414 21. Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. JAMA. 2017;318(19):1925-6.
- 415 22. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, et al. Age,
- 416 Gene/Environment Susceptibility Reykjavik Study: Multidisciplinary Applied Phenomics. Am J
- 417 Epidemiol. 2007;165(9):1076-87.
- 418 23. Gudmundsson G, Margretardottir OB, Sigurdsson MI, Harris TB, Launer LJ, Sigurdsson S, et
- al. Airflow obstruction, atherosclerosis and cardiovascular risk factors in the AGES Reykjavik study.
- 420 Atherosclerosis. 2016;252:122-7.
- 421 24. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ, et
- al. A genome-wide association study of serum proteins reveals shared loci with common diseases.
- 423 Nat Commun. 2022;13(1):480.
- 424 25. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the
- general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-87.
- 426 26. Boyle El, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, et al. GO::TermFinder--open source
- 427 software for accessing Gene Ontology information and finding significantly enriched Gene Ontology
- terms associated with a list of genes. Bioinformatics. 2004;20(18):3710-5.
- 429 27. Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al. New
- 430 genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease
- associations across multiple ancestries. Nat Genet. 2019;51(3):481-93.
- 432 28. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental
- variables in Mendelian randomization: comparison of allele score and summarized data methods.
- 434 Stat Med. 2016;35(11):1880-906.
- 435 29. Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al. New
- 436 genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease
- associations across multiple ancestries. Nat Genet. 2019;51(3):481-93.
- 438 30. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al.
- 439 Large-scale integration of the plasma proteome with genetics and disease. Nat Genet.
- 440 2021;53(12):1712-21.
- 441 31. Zou Y, Carbonetto P, Wang G, Stephens M. Fine-mapping from summary data with the "Sum
- 442 of Single Effects" model. PLoS Genet. 2022;18(7):e1010299.
- 443 32. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference
- 444 for human genetic variation. Nature. 2015;526(7571):68-74.
- 445 33. Wen X, Pique-Regi R, Luca F. Integrating molecular QTL data into genome-wide genetic
- 446 association analysis: Probabilistic assessment of enrichment and colocalization. PLoS Genet.
- 447 2017;13(3):e1006646.
- 448 34. Hukku A, Pividori M, Luca F, Pique-Regi R, Im HK, Wen X. Probabilistic colocalization of
- 449 genetic variants from complex and molecular traits: promise and limitations. Am J Hum Genet.
- 450 2021;108(1):25-35.
- 451 35. Kim M, Vo DD, Kumagai ME, Jops CT, Gandal MJ. GeneticsMakie.jl: a versatile and scalable
- 452 toolkit for visualizing locus-level genetic and genomic data. Bioinformatics. 2023;39(1).
- 453 36. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the
- 454 human plasma proteome. Nature. 2018;558(7708):73-9.
- 455 37. Gudmundsdottir V, Zaghlool SB, Emilsson V, Aspelund T, Ilkov M, Gudmundsson EF, et al.
- 456 Circulating Protein Signatures and Causal Candidates for Type 2 Diabetes. Diabetes.
- 457 2020;69(8):1843-53.
- 458 38. Zhang K, Li M, Yin L, Fu G, Liu Z. Role of thrombospondin 21 and thrombospondin 22 in
- 459 cardiovascular diseases (Review). Int J Mol Med. 2020;45(5):1275-93.

- 460 39. Jiang YM, Yu DL, Hou GX, Jiang JL, Zhou Q, Xu XF. Serum thrombospondin-2 is a candidate
- diagnosis biomarker for early non-small-cell lung cancer. Biosci Rep. 2019;39(7).
- 462 40. Calabro NE, Kristofik NJ, Kyriakides TR. Thrombospondin-2 and extracellular matrix
- 463 assembly. Biochim Biophys Acta. 2014;1840(8):2396-402.
- 464 41. Zito E, Chin KT, Blais J, Harding HP, Ron D. ERO1-beta, a pancreas-specific disulfide oxidase,
- promotes insulin biogenesis and glucose homeostasis. J Cell Biol. 2010;188(6):821-32.
- 466 42. Asada K, Kobayashi K, Joutard S, Tubaki M, Takahashi S, Takasawa K, et al. Uncovering
- 467 Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer. Biomolecules.
- 468 2020;10(4).
- 469 43. Zhu T, Gao YF, Chen YX, Wang ZB, Yin JY, Mao XY, et al. Genome-scale analysis identifies
- 470 GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget.
- 471 2017;8(13):21281-9.
- 472 44. Li H, Liu Y, Wang L, Shen T, Du W, Liu Z, et al. High apolipoprotein M serum levels correlate
- with chronic obstructive pulmonary disease. Lipids Health Dis. 2016;15:59.
- 474 45. Burkart KM, Manichaikul A, Wilk JB, Ahmed FS, Burke GL, Enright P, et al. APOM and high-
- 475 density lipoprotein cholesterol are associated with lung function and per cent emphysema. Eur
- 476 Respir J. 2014;43(4):1003-17.
- 477 46. Strnad P, McElvaney NG, Lomas DA. Alpha1-Antitrypsin Deficiency. N Engl J Med.
- 478 2020;382(15):1443-55.
- 47. Senn O, Russi EW, Schindler C, Imboden M, von Eckardstein A, Brändli O, et al. Circulating
- 480 alpha1-antitrypsin in the general population: Determinants and association with lung function.
- 481 Respir Res. 2008;9(1):35.
- 48. Thun G-A, Ferrarotti I, Imboden M, Rochat T, Gerbase M, Kronenberg F, et al. SERPINA1 PiZ
- and PiS Heterozygotes and Lung Function Decline in the SAPALDIA Cohort. PLoS One.
- 484 2012;7(8):e42728.
- 485 49. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking status and tumor necrosis
- 486 factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond). 2010;7:29.
- 487 50. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumor necrosis factor-alpha drives 70%
- of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med. 2004;170(5):492-
- 489 8.
- 490 51. Yao Y, Zhou J, Diao X, Wang S. Association between tumor necrosis factor-α and chronic
- 491 obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis.
- 492 2019;13:1753466619866096.
- 493 52. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of
- 494 infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med.
- 495 2007;175(9):926-34.
- 496 53. Koo HK, Hong Y, Lim MN, Yim JJ, Kim WJ. Relationship between plasma matrix
- 497 metalloproteinase levels, pulmonary function, bronchodilator response, and emphysema severity.
- 498 Int J Chron Obstruct Pulmon Dis. 2016;11:1129-37.
- 499 54. Churg A, Zhou S, Wright JL. Matrix metalloproteinases in COPD. Eur Respir J. 2012;39(1):197.
- 500 55. Navratilova Z, Zatloukal J, Kriegova EVA, Kolek V, Petrek M. Simultaneous up-regulation of
- matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of
- patients with chronic obstructive pulmonary disease. Respirology. 2012;17(6):1006-12.
- 503 56. Regueiro V, Campos MA, Morey P, Sauleda J, Agustí AGN, Garmendia J, et al.
- 504 Lipopolysaccharide-binding protein and CD14 are increased in the bronchoalveolar lavage fluid of
- 505 smokers. Eur Respir J. 2009;33(2):273.
- 506 57. de Lau WB, Snel B, Clevers HC. The R-spondin protein family. Genome Biol. 2012;13(3):242.
- 507 58. Su Y, Zhang X, Bidlingmaier S, Behrens CR, Lee NK, Liu B. ALPPL2 Is a Highly Specific and
- Targetable Tumor Cell Surface Antigen. Cancer Res. 2020;80(20):4552-64.
- 509 59. Jung IH, Elenbaas JS, Alisio A, Santana K, Young EP, Kang CJ, et al. SVEP1 is a human coronary
- artery disease locus that promotes atherosclerosis. Sci Transl Med. 2021;13(586).

- 511 60. Merali S, Barrero CA, Bowler RP, Chen DE, Criner G, Braverman A, et al. Analysis of the
- 512 plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling.
- 513 COPD: Journal of Chronic Obstructive Pulmonary Disease. 2014;11(2):177-89.











